Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España

Smolen, 2010, Treating rheumatoid arthritis to target: Recommendations of an international task force, Ann Rheum Dis, 69, 631, 10.1136/ard.2009.123919 Singh, 2012, 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care Res (Hoboken), 64, 625, 10.1002/acr.21641 Combe, 2007, EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT), Ann Rheum Dis, 66, 34, 10.1136/ard.2005.044354 Smolen, 2010, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Ann Rheum Dis, 69, 964, 10.1136/ard.2009.126532 PROYECTO EMAR II. Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en España. Sociedad Española de Reumatología (consultado 5 Dic 2013). Disponible en: http://www.ser.es/ArchivosDESCARGABLES/Proyectos/Emar/EMAR_Informe.pdf Blanco, 2011, Estudio descriptivo de la utilización de los FAME en los pacientes con artritis reumatoide o artritis persistente que inician tratamiento farmacológico en España (ESTUDIO FIRST), Reumatol Clin, 7, 88, 10.1016/j.reuma.2010.03.007 Emery, 2009, Arthritis Rheum, 60, 2272, 10.1002/art.24638 Keystone, 2009, Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study, Ann Rheum Dis, 68, 789, 10.1136/ard.2008.099010 Smolen, 2009, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase iii trial, Lancet, 374, 210, 10.1016/S0140-6736(09)60506-7 Emery, 2011, The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy, Arthritis Rheum, 63, 1200, 10.1002/art.30263 Combe, 2013, Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: Results of the GO-MORE study, Ann Rheum Dis Ficha Técnica SIMPONI [consultado 10 Abril 2014]. Disponible en: Agencia Española de Medicamentos y Productos Sanitarios Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf Durez, 2013, Remission rates during golimumab treatment for rheumatoid arthritis are associated with differences in baseline disease states across geographic regions in the GO-MORE study, Ann Rheum Dis, 72, 872, 10.1136/annrheumdis-2013-eular.2603 Burmester, 2007, Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial, Ann Rheum Dis, 66, 732, 10.1136/ard.2006.066761